Prerpints.org logo
Preprint
Review

Emerging Pharmaceutical Therapies to Address the Inadequacy of Gluten-Free Diet for Celiac Disease

Altmetrics

Downloads

228

Views

53

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

04 November 2023

Posted:

06 November 2023

You are already at the latest version

Alerts
Abstract
.Celiac disease (CeD) is a chronic, autoimmune disorder triggered by the ingestion of gluten, affecting around 1% of the global population. It is a multifactorial disease involving both genetics and environ-mental factors. Nowadays, the only available treatment for CeD is a life-long gluten-free diet (GFD), which can cause a significant burden for patients, since symptoms and mucosal injury can persist de-spite apparent compliance with a GFD. That could also lead to psychological consequences and affect the quality of life of these patients. Thankfully, recent advances in understanding the pathogenesis of CeD and the availability of various targets have made it feasible to explore pharmaceutical treatments specific to CeD. Recently, the FDA has highlighted the unmet needs of adult patients on GFD who expe-rience ongoing symptoms attributed to CeD and also show persistent duodenal villous atrophy. This re-view will outline the limitations of a GFD, describe the targets of potential novel treatment of CeD and provide an overview of the primary clinical trials involving oral and injectable agents for a non-dietary treatment of CeD.
Keywords: 
Subject: Medicine and Pharmacology  -   Gastroenterology and Hepatology

1. Introduction

Celiac disease (CeD) is a chronic, autoimmune disorder triggered by the ingestion of gluten, affecting around 1% of the global population [1,2] . It is a multifactorial disease involving both genetics and environmental factors [3] . Genetical susceptibility to CeD is conveyed by genes facilitating a potent adaptive immune response directed against deamidated gluten peptides, which include at least one copy of both major histocompatibility complex class II (MHC-class II) genes encoding HLA-DQ2.5 in about 90% of patients or otherwise HLA-DQ8, DQ2.2 or DQ7 [4] . The MHC-class II genes are indeed the driving genetic factor for CeD, but there are numerous non-MHC genes that can increase the risk for CeD, which are primarily located in non-coding regions [5,6]. The MHC-class II genes coding susceptible HLA-DQ polymorphisms are necessary but not sufficient for the development of the disease; their absence is helpful to exclude the diagnosis of CeD in case of equivocal small bowel histological findings [7]. The critical environmental factor essential for the development of CeD is the enteric exposure to gluten, which comprises a diverse group of proline- and glutamine-rich water-insoluble proteins (prolamins). Prolamins are common to many cereals as seed storage proteins, but only wheat, barley, and rye provide prolamins with clinical toxicity in patients with CeD. Wheat gliadins and the related hordeins in barley and secalins in rye are the most potent proteins reactivating the adaptive immune response to gluten in patients with CeD [8]. Regions of these proteins rich in proline and glutamine are relatively resistant to human brush border and pancreatic endopeptidases. Consequently, intact gliadin peptides sufficiently large to be immunogenic are relatively abundant and available for paracellular or immunoglobulin A (IgA)-facilitated transcellular transport across the intestinal epithelium into the lamina propria. These relatively large gliadin peptides acquire immunogenicity following partial deamidation occurring before or during the course of absorption. Transglutaminase 2 (TG2), formerly known as tissue transglutaminase, expressed in apoptotic and injured cells in the gut has been implicated as the host enzyme responsible for facilitating gluten immunotoxicity in celiac disease. TG2 selectively deamidates gliadin peptides yielding two distinct products that activate either CD4+ T cells via T cell receptor (soluble deamidated gliadin peptide, DGP) or they bind soluble B-cell surface-bound immunoglobulin (B cell receptor). TG2 in acidic conditions catalyses direct deamidation of glutamine incorporated in peptide to glutamate producing DGPs. Alternatively, TG2 in neutral and alkaline conditions catalyses transamidation linking peptide glutamine to amines such as lysine residues in proteins that allows for the formation of deamidated gliadin-TG2 complexes that function as highly immunogenic hapten-carrier complexes driving both DGP-specific CD4+ T cells and B cells specific for DGP or TG2. CD4+ T cell recognition of DGPs is facilitated firstly because selective deamidation substantially increases the binding avidity of many gliadin peptides for HLA-DQ2.5 and/or HLA-DQ8 preferentially expressed on the surface of professional antigen-presenting cells (dendritic cells and B cells). CD4+ T cell recognition of DGPs is also facilitated by DGP-TG2 complexes because specific B cells (for DGP and TG2) are exceptionally efficient antigen presenting cells allowing immune recognition of tiny amounts of DGP that would be impossible with dendritic cells or macrophages alone. In summary, gut digestive proteases and TG2 along with facilitated transepithelial transport are understood as key steps in delivering sufficient gluten antigen to allow dendritic cells activated by innate stimuli to drive maturation of naïve DGP-specific CD4+ T cells (disease induction), and also for DGP- and TG2-specific B cells to drive highly efficient reactivation and expansion of memory DGP-specific CD4+ T cells in established disease. Cytokine and chemokine release by activated DGP-specific CD4+ T cells directly injures epithelial cells, recruits and activates innate immune cells to amplify intestinal injury, expands the population of DGP-specific CD4+ cells and TG2 and DGP-specific B cells, and also drives B cell maturation to produce plasma cells secreting IgA and IgG specific for TG2 and DGP. The cooperative interaction between IL-15 (produced by injured intestinal epithelial) and cytokines (derived from the activation of CD4+ T cells and innate immune cells) lead to the differentiation of intraepithelial lymphocytes (IEL) into cytotoxic CD8+ T cells [9,10,11]. One of the pathways activated by these cytokines is the Janus kinase 1-signal transducer and activator of the transcription 3 (JAK1-STAT3) pathway. The inflammatory cascade and cytotoxic CD8+ T cells damage the intestinal mucosa and cause apoptosis. In the presence of proinflammatory cytokines, there is also a low concentration of TGFβ, which promotes CD4+ T helper 17 (Th17) differentiation. Gliadin-specific Th17 CD4+ T cells produce proinflammatory cytokines and mucosa-protective cytokine IL-22 and is an effector memory cell [12]. In established CeD, gluten ingestion drives cytokine (interleukin-2, IL-2) release from specific CD4+ T cells that can be measured in plasma within two hours and correlates with severity and onset of acute symptoms [13,14,15,16].
Sustained gluten exposure for at least several days or weeks is necessary to induce histological injury in the duodenum characterised by deepening of crypts, shortening of villi, more frequent IELs, and infiltration of the lamina propria by acute and chronic inflammatory cells including B cells and plasma cells [17].

2. Gluten- Free Diet

The only available “specific” treatment for CeD is life-long removal of the causative antigen: gluten free diet (GFD). This therapy has been known since the 1940s when Willem Dicke identified wheat intake as a cause for reactivation of CeD (Winter Starvation 1944-45). Strict adherence to GFD is associated with reduction in serum levels coeliac-related TG2 IgA and DGP IgG, complete or more often partial recovery of the intestinal mucosa, resolution of iron and nutritional deficiencies, and reduction of long-term complications [18]. GFD is palliation rather than a cure because the adaptive immune response to deamidated gluten persists, and in fact many patients on GFD report being more symptomatic following gluten ingestion than when they regularly consumed gluten. Indeed, DGP-specific memory CD4+ T cells circulate in blood of CeD patients at frequencies only modestly lower than in patients with untreated CeD [19]. Patients on GFD are susceptible to sometimes severe acute gluten-induced toxicity associated with systemic cytokine release [14,16]. GFD practiced by most patients achieves a substantial quantitative reduction in known ingestion of gluten. GFD, however, does not eliminate inadvertent gluten exposure resulting from cross-contamination, incorrect or misinterpreted food labelling, or ignorance of food vendors and providers unknowingly serving food containing gluten. GFD rarely achieves exclusion of all dietary gluten evidenced by persistent mucosal injury in most patients who appear to be well controlled on GFD [20]. Despite the benefits that GFD can give, many patients are not satisfied with a GFD and desire a novel, proactive therapy which could control gluten-associated symptoms, reduce the burden of a GFD, and improve Quality of life (QoL) [21,22,23] . Physicians and regulators on the other hand are focused on persistent tissue injury and seek treatments that improve objective assessments of intestinal damage such as villous atrophy [24].
Many patients fear gluten contamination. Efforts to study dose-dependent effects of chronic ingestion of a small amount of gliadin on duodenal histology began over 30 years ago [25]. Assessment of histological deterioration is challenging but appeared to be more pronounced in children ingesting 300 mg of gluten daily than those with a daily gluten dose of 100 mg. Subsequently, Catassi et al. performed a prospective, randomized, double-blind, placebo-controlled study with patients receiving placebo or 10 mg or 50 mg of gluten for 3 months. In this highly cited study, Catassi et al. concluded that ingesting 50 mg gluten daily for 3 months caused mucosal injury in the second part of the duodenum assessed by significant decrease in villous height (Vh) to crypt depth (Cd) ratio, Vh:Cd [26]. A systematic review in 2008 concluded that a daily gluten intake of < 10 mg is unlikely to cause significant abnormalities detectable by conventional histology [27]. Unintentional ongoing gluten exposure is more common than commonly believed, even when patients self-report excellent/good GFD adherence. Traces of gluten contamination could be a contributing factor to persistent villous atrophy and lack of clinical recovery [28,29].
Whether weeks or months-long gluten challenge with 10 mg or 50 mg is a valid method to quantitate the upper level of gluten tolerated by patients has been brought into question by more recent studies measuring faecal gluten immunogenic peptides (GIPs) showing many patients on GFD often inadvertently ingest about 150 mg [30].
In addition, rigorous validation of Vh:Cd, or of Vh or Cd alone in adjacent villus-crypt units has led to an appreciation that very few CD patients on GFD achieve “normal” Vh:Cd with about half having persistent villous atrophy [31]. As a potentially more sensitive alternative to second part of the duodenum histology after extended gluten challenge, systemic IL-2 release within hours after gluten ingestion may be a more sensitive and flexible readout of gluten toxicity [13,32]. The results of an ongoing study utilising double-blind single bolus gluten challenge with assessments of serum IL-2 to determine the lower level of gluten toxicity are awaited with interest (ACTRN12621000781842).
The risk of contamination and the difficulty of diet adherence make the GFD a restrictive diet affecting the patient's Quality of life (QoL) and impacting social events, relationships, and work. Previous literature has paid attention to the QoL of CeD patients, both at diagnosis and while on a GFD, mainly finding a reduction in QoL at diagnosis, which improves once on a GFD [33]. Nachman et al. observed that QoL and depression scales were significantly worse at 4 years post-diagnosis compared with 1 year, even if the scores remained significantly better than those at diagnosis [34], finding that low adherence to a GFD mainly impacted QoL. A year later, Barratt et al. found that the perceived degree of difficulty adhering to a GFD impacted QoL [35]. In a systematic review by Burger et al., the authors assessed that a GFD significantly improves but does not normalize health-related quality of life, confirming that better dietary adherence results in higher QoL [36]. Marsilio et al. found that non-compliant GFD patients appeared to suffer from dysphoria, a generalized dissatisfaction with life [37]. A prospective study has recently reported an improvement in QoL and psychological disorders after one and two years on a GFD, describing dietary compliance as the leading risk factor [38,39].
Even when the GFD is well done, another point recently underlined is the risk of developing metabolic syndrome and fatty liver [40,41]. Rispo et al. have recently described an increased risk of metabolic-associated fatty liver disease (MAFLD) in CeD patients on a GFD [42]. The authors found that 46.6% of patients developed NAFLD at two years of follow-up, while 32.6% had MAFLD. However, other studies have found contrasting results [43,44,45].
Finally, the literature describes that 7-30% of CeD patients are defined as slow responders, since they continue to have symptoms, signs or laboratory abnormalities of CeD after at least 6-12 months of GFD [46]. In these cases, a differential diagnosis is required, and it is based firstly on a review of the original diagnosis: the available results of biopsy at the diagnosis, serology, and/or HLA-DQ2/DQ8 should be analysed. If CeD is confirmed, the unintentional ingestion of gluten is the most common cause of slow-responder patients (35-50% of cases). Dietary compliance should be the keystone of further evaluations (for example, detecting immunogenic gluten peptides in stool or urine) [47]. CeD serology could also be helpful, but it must be considered that a routine serology doesn't exclude low-level gluten ingestion [48]. Small bowel histology of new biopsy leads to the differential diagnosis once the dietary aetiology is excluded. The possible causes for persistent symptoms include irritable bowel syndrome, microscopic colitis, lactose intolerances, bile acid diarrhoea and only rarely refractory CeD [46]. In conclusion, life-long GFD is the only supportive care now available for management of CeD and presents a significant burden for patients; however, strict adherence seldom completely eliminates dietary gluten and symptoms and mucosal injury can persist despite apparent compliance with GFD. Fortunately, CeD-specific pharmaceutical development is now possible because CeD immuno-pathogenesis is now relatively well understood and a variety of biomarkers are available to assess therapeutic efficacy.

3. Pharmaceutical adjuncts to GFD

Indications for pharmaceutical agents are likely to be as adjunct rather than replacements for GFD [24]. Many CeD patients already have access to “over-the-counter” supplements that claim to provide some relief or protection from the effects of gluten, however, there is no pharmaceutical agent that has yet received approval from regulatory agencies for “treatment” of gastrointestinal effects of CeD. Dapsone, however, is approved by the United States Food and Drug Administration (FDA) for the treatment of dermatitis herpetiformis, a classical but uncommon skin manifestation of CeD [49]. The 2022 draft regulatory guidance from the FDA highlights the unmet needs of adult patients on GFD who experience ongoing symptoms attributed to CeD and also show persistent duodenal villous atrophy [24]. In addition to national regulatory approvals, availability of drugs for CeD patients would also be shaped by payers including government agencies seeking cost-effective as well as efficacious medications. This would be a notable change as patients and family currently bear most or all the cost of treatment with GFD, and for many patients the role of the physician in disease management is minimal after diagnosis is made.
The FDA statement anticipates drug approvals for CeD that would be prescribed by physicians and foreshadows unpreceded changes in clinical management of CeD. Presumably, in the future, gastroenterologists will serve as key players in selecting CeD patients likely to benefit from new therapies. This may present a significant challenge since many patients are not followed after diagnosis in specialist clinics, and few have regular follow-up endoscopies to assess mucosal health even though reports linked to sponsored clinical trials suggest at least half of patients apparently well controlled on GFD have persistent villous atrophy (Marsh 3) and most of the remainder have crypt hyperplasia (Marsh 2) [50,51].
As clinical care of CeD enters the pharmaceutical era, capsule endoscopy to assess anatomical extent of intestinal involvement and blood tests capable of detecting CeD-associated gluten immunity may become useful clinical tools. Blood tests measuring circulating gluten-specific CD4+ T cells or measuring IL-2 in serum after bolus gluten challenge could confirm CeD diagnosis and possibly also stratify disease severity based on the “strength” of immune response to gluten in vivo [15,52,53]. A further challenge is misdiagnosis of CeD amongst patients on GFD, which may be rather common in patients who have normalised histology [54]. In contrast to a negative CeD-serology result in a patient on GFD, a negative blood test measuring gluten-specific T-cell immunity may allow resumption of an unrestricted diet in many patients strictly avoiding gluten [54].

4. Delivery and administration of pharmaceutical adjuncts to GFD

Investigational products under development for CeD are delivered either orally or by subcutaneous or intravenous routes. Oral medications may require administration strictly timed before meals to be effective. For example, unless the possibility of gluten exposure can be anticipated, glutenases digesting gluten contaminants may be needed before every meal or snack. Potentially, the same rigorous compliance may also be needed for oral inhibitors of TG2 if their duration of action is short. In contrast, injectables that aim to desensitize or tolerize the immune system to gluten would be expected to act over weeks or months allwing greater flexibility in frequency of dosing but would impose on patients the responsibility for self-injection or presenting to hospital- or community-based infusion clinics. In either scenario, gastroenterologists would be expected to monitor effectiveness and guide selections of alternative medications in case of treatment failure.

5. Potential Therapeutic Targets in Celiac Disease

5.1. Oral Agents

5.1.1. Steroids

Glucocorticoids are potent inhibitors of inflammation through the suppression of B cells and of cytokine production by regulatory T cells (Figure 1, point 8) [55] . The use of corticosteroids in CeD has been tested for the treatment of non-responsive celiac disease (NRCD) to a gluten free diet and represents one of the few treatments available when the non-response is due to a refractory celiac disease [56]. Since the use of systemic corticosteroids is limited by systemic side effects, budesonide, a micronized corticosteroid with high topical effect and with low bioavailability, represents an attractive alternative.
In 2018, a single-center, randomised, open-label trial aimed to evaluate the effect of a short course of prednisolone combined with a GFD on the recovery of celiac disease. Fourteen new diagnosed CeD children were randomized into the GFD only and 14 into GFD with prednisolone (1 mg/kg for four weeks). The use of prednisolone did not report a different clinical and serological recovery but a rapid improvement of histological recovery at 8 weeks, however there was no difference in overall histological improvement at 12 months after starting treatment [57]. Recently, the benefit of a 3 months treatment with budesonide in children with NRCD was observed [58]. Budesonide was also tested to induce clinical response in adults with NRCD, showing a more response in those with diarrhoea and less in those with fatigue or other extraintestinal [59]. The authors also observed that in individuals with RCD, short courses of budesonide were associated with high risk of clinical recurrence and lack of mucosal recovery, underlying that in these patients, a longer course could be more effective, as shown in Mayo Clinic’s recent series [60]. In this latter retrospective study, budesonide was given 3 times daily as an opened 3 mg enteric-coated capsule. The first and the second daily capsule were opened, placed into apple sauce and swallowed with water; the third daily capsule instead was swallowed intact. With this protocol they let the drug reach the entire small bowel. The authors observed that budesonide was able to induce clinical and histologic response in patients affected by RCD I and RCD II, regardless of previous treatment with immunosuppressants (azathioprine) or systemic steroids. Malamut et al. showed complete normalization of the mucosa in only 4 out of 10 patients with RCD-1 taking systemic corticosteroids [61]. A second and less common indication of corticosteroids could be celiac crisis, that is defined as acute onset or rapid progression of gastrointestinal symptoms and it requires hospitalization. In 2020 a retrospective study, in which 11 patients with celiac crisis were involved, showed a rapid clinical improvement within 2 weeks in patients who received corticosteroids at dosage of 30 mg, 40 mg or 60 mg [62].
Finally, dapsone is the only Food and Drug Administration (FDA) approved drug used in the treatment of dermatitis herpetiformis and is the drug of choice if a gluten-free diet modification is not an option, for whatever reason [63,64].

5.1.2. tTG Inhibition

Transglutaminase 2 (TG2) is an antigen expressed in the intestinal mucosa which has as target gliadin peptides, and it deamidates neutral glutamine residues into negatively charged glutamic acid. Due to this modification, deaminated gliadin peptides bind with high avidity HLA-DQ2 or HLA-DQ8 molecules on mucosal antigen–presenting cells and then activate gluten peptide-specific CD4+ TH1 cells (Figure 1, point 4) [65].
ZED1227 is an investigational pharmaceutical that is an active site-directed TG2 inhibitor that prevents the deamidation of gluten and the production of proinflammatory cytokines. ZED1227 was effective and safe in phase 1 clinical trials that involved more than 100 healthy individuals exposed to up to 500 mg (EudraCT numbers, 2014-003044-13 and 2015-005283-42). A phase 2 clinical study compared patients with well-controlled CeD exposed to placebo to patients who underwent a daily gluten challenge for six weeks at 3 doses of ZED 1227 (10 mg, 50 mg, 100 mg). It assessed that this drug reduced gluten-induced duodenal mucosal injury (EudraCT number, 2017-002241-30) [66]. Based on these clinical data, a phase 2b “real-life” study started in 2021 that evaluates the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite a gluten-free diet is still ongoing (Eudra CT number2020-004612-97).

5.1.3. Glutenase

As reported above (Figure 1, point 1), the undigested gliadin peptides are proline-rich and resistant to proteolytic degradation. They can cross the tight junctions and reach the lamina propria, activating proinflammatory cascades. Therefore, drugs have been designed to sequester gluten in the intestinal lumen or/and improve its intraluminal digestion.
ALV003 (or Latiglutinase) is an investigational pharmaceutical that is orally administered mixture of two recombinant proteases: ALV001, a cysteine endoprotease B-isoform and ALV002, a prolyl endopeptidase. In two phase 1 clinical trials (NCT00626184, NCT00669825), drug was administered in the fasted state (study 1, N 28) and with a gluten-containing meal (study 2, N=53) and no serious adverse events or reactions were reported at all dose levels of ALV003 (100, 300, 900, and 1800 mg [67].
In two phase 2 double-blind, placebo-controlled clinical trials, well-controlled CeD patients underwent a daily gluten challenge (2 gr). Sixteen patients given ALV003 and 18 given placebo were evaluated. After 6-weeks of treatment, ALV003 attenuated gluten-induced intestinal mucosal injury (NCT00959114, NCT01255696) [68].
Moreover, another clinical trial assessed the efficacy and safety of Latiglutenase in 494 CeD patients (NCT01917630). Participants on a GFD for at least 1 year with persistent moderate or severe symptoms and villous atrophy were assigned randomly to groups given placebo or 100, 300, 450, 600, or 900 mg latiglutenase daily for 12 or 24 weeks. ALV003 didn't improve histologic and symptom scores compared to placebo [69]. However, seropositive patients showed symptoms (abdominal pain and bloating) and QoL benefits from using Latiglutenase with meals compared to placebo [70].
Recently, in a placebo-controlled phase IIb study, in which 21 celiac patients were exposed to 2 gr of gluten per day for six weeks compared to 22 patients exposed to placebo, Murray et al. reported that Latiglutenase (IMGX003) was able to reduce gluten-induced intestinal mucosal damage and symptom severity (NCT03585478) [71]. In this study measurements of gluten-immunogenic peptides (GIP) in urine were used to demonstrate the mechanism of action for this enzyme; indeed, the measurements of GIP in urine indicated 95% gluten degradation in the stomach by Latiglutenase. A phase 2 RCT (NCT04243551) is ongoing and aims to evaluate the symptom severity reduction as a primary endpoint in patients with CeD exposed to periodic gluten exposure for 6 weeks.
TAK-062 is an investigational pharmaceutical that is effective endopeptidase, degrading in vitro, more than 99% of gluten (3 g and 9 g) within 10 minutes. In a phase I dose escalation study, conducted in healthy participants and CeD patients, Pultz et al. reported that TAK-062 was well tolerated and, for complex meals (1-6 g gluten), analysing the aspiration of stomach continent, was found a median gluten degradation ranging from 97% to more than 99% [72]. A phase 2 RCT (NCT05353985) in patients with active CeD is still ongoing and expected to be completed in May 2025.
AN-PEP is a food supplement an Aspergillus niger-derived endopeptidase that led to luminal gluten detoxification. Salden et al. and König J et al. have assessed the efficacy of AN-PEP in degrading gluten in the stomach of healthy volunteers or gluten-sensitive subjects [73,74]. The efficacy of this endopeptidase on symptoms was tested in a randomised double-blind placebo-controlled pilot study which showed no symptomatic advantages over placebo among the 14 involved patients, who had to consume a gluten-containing food product (toast) with AN-PEP for 2 weeks (NCT00810654) [75]. Furthermore, a phase IV clinical trial has investigated the effect of daily administration of AN-PEP compared to placebo in terms of frequency and concentration of GIP excretion in stool and urine episodes in 4 weeks. Forty CeD patients were enrolled and even if it has been completed on July 2022, the results are not yet available (NCT04788797).

5.1.4. Intestinal regeneration

Once the CD4+ T-cells are activated by antigen-presenting cells, they secrete various cytokines such as IFNγ and IL-21, resulting in an immune cascade that leads to mucosal damage. The mucosal morphological changes in CeD are mainly represented by increased intraepithelial lymphocytes (IELs) with or without villous atrophy of the duodenal mucosa (Figure 1, point 9).
IMU 856 is an epigenetic regulator that enhances the normal physiological process of gut wall renewal, aiming to restore villous architecture by regenerative process of the epithelial lining. IMU 856 acts as a small molecule regulator that stabilizes and enhances the expression of SIRT6 (Sirtuin 6). This protein serves as a transcriptional regulator of intestinal barrier function and regenerates the bowel epithelium [76].
Phase 1/ 1b trials are only published in the Australian trial register, and only Phase 1b was published in May 2023 [77,78]. It evaluated patients with a well-controlled CeD receiving 28-day treatment of 80 mg or 160 mg of IMU 856 compared to the placebo arm. It was shown that IMU -856 has beneficial effects on symptoms over placebo, prevents histological damage and enhances nutrient uptake (Zinc, vitamin B12). There is also an improvement in citrullin, a biomarker that reflects the health status of enterocytes and a reduction of IL-2 levels. IMU-856 was safe and well-tolerated, and the highest incidence of adverse effects derived from the high prevalence of ongoing active coeliac disease patients. Phase 2b clinical trial in ongoing active CeD. The Immunic product IMU-856 P1b/2a was reported in May at DDW see abstract and press release – positive [79].

5.1.5. Tight junction modulators

Enterocytes are joined together by tight junctions, whose abnormalities underlie the CeD pathogenesis and let indigestible gluten fragments reach lamina propria and create immunostimulatory epitopes (Figure 1, point 3). AT 1001, or Larazotide Acetate is an investigational pharmaceutical that an is oral peptide derived from the zonula occludens toxin secreted by Vibrio cholera. Due to the pathogenic role of zonulin-dependent intestinal barrier permeability, AT1001 was tested in celiac patients in different clinical trials (NCT01396213, NCT00620451, NCT00362856, NCT00492960).
A systematic review, in which only four RCTs (626 patients) met the eligibility criteria (AT-1001, n=465, placebo, n=161), concluded that Larazotide acetate is well-tolerated and improves symptoms in patients with CeD, particularly those undergoing gluten challenge. On the other hand, the superiority of Larazotide acetate over placebo in reducing intestinal permeability was not reported because the pooled analysis of the change in urinary LAMA ratio did not significantly differ between AT-1001 and placebo groups [80]. The implications on histologic improvement or immunologic sequelae of Larazotide are still unknown.
Interim analysis led to discontinuation of a recent placebo-controlled Phase III clinical trial which enrolled 525 coeliac patients with persistent symptoms [81]. This study aimed to evaluate the efficacy and safety of Larazotide Acetate for relieving persistent symptoms in adult patients with coeliac disease on a gluten free diet (NCT03569007).

5.1.6. Gluten sequestration

Anti-gluten antibody
AGY is an encapsulated oral egg yolk anti-gliadin polyclonal antibody that neutralizes all CeD-inducing prolamins due to its cross-reactivity (Figure 1, point 2). In the phase 1 open-label trial with a cohort of ten patients on a GFD, AGY improved Quality of life, lowered antibodies, and lowered LMER (lactulose mannitol excretion ratios) when taking before meals [82]. A phase 2 RCT that evaluates the effect of AGY on celiac symptoms is ongoing (NCT 03707730).
Polymeric binders
BL-7010 is a copolymer poly (hydroxyethyl methacrylate-co-styrene sulfonate) (P(HEMA-co-SS) that binds with higher efficacy to gliadin and protects it from enzymatic cleavage by digestive enzymes, preventing the formation of immunogenic peptides. It was shown that BL-7010 was effective at abrogating gluten-associated pathology in gliadin-sensitized NOD-DQ8 mice. Still, it was also correlated with the decrease of TNF-α in response to gliadin in mucosal biopsy specimens of patients with CeD [83,84]. In 2014, RCT enrolled 40 celiac patients, testing the single and the repeated single administration of these drugs, but the results are still unknown (NCT01990885).

5.1.7. Cytokine inhibition

Tofacitinib is a pan-JAK inhibitor and is approved to treat inflammatory bowel diseases and rheumatoid arthritis (Figure 1, point 7). Yokoyama S et al. point out the potential value of tofacitinib as a therapy for RCD because they observed a lasting reversal of pathologic manifestations in a transgenic mouse model of CeD treated with tofacitinib [85]. A single report of RCD remission in response to tofacitinib is reported [86]. A phase 2 open-label trial of tofacitinib in type II RCD is ongoing (Eudra CT: 2018-001678-10).
Another therapeutic target is a CCR9 receptor antagonist. CCR9 is a small intestinal homing receptor that leads to the migration of lymphocytes to the intestine. A phase 2a clinical trial evaluates the effect of CCX282-B on the villous height/crypt depth ratio in CeD patients on a strict GFD compared to placebo (NCT00540657). Even if the study is completed, the results have yet to be published. Further data are required to determine the safety of these drugs.

5.1.8. Gut microbiome

Differences in the microbiota have been reported in many inflammatory intestinal diseases and CeD [87] (Figure 1, point 10). Microbiota and their metabolites have been supposed to play a role in gluten metabolism and, consequently, in CeD onset and severity. They may regulate the permeability of the intestinal barrier and the modulation of the adaptive and innate immune responses [88,89,90]. Recently, a published study has shown that probiotic Lactobacillus strains have enzymatic abilities for hydrolyzing gluten peptides [91]. Furthermore, distinct Bifidobacteria attenuate gliadin-induced immunopathology by producing a serine protease inhibitor (Srp) (92). A double-blind placebo-controlled study on paediatrics patients assessed that Bifidobacterium longum CECT 7347 was able to reduce immune markers (serum TNF, IgA in stool and peripheral CD3+ T cells), as also proven in other randomized trials on Bifidobacterium breve strains (B632, BR03) [93,94,95,96,97].
A recent meta-analysis performed in 2020 assessed that probiotics could improve gastrointestinal symptoms in CeD patients, while there was insufficient data on the QoL and tumor necrosis factor-a levels [98]. RCTs on the effect of probiotics on mucosal recovery are still lacking, and nowadays, guidelines don't recommend probiotic use in CeD patients. Research in this field is needed in the future.

5.2. Injectable Agents

5.2.1. Cytokine inhibition

Interleukin-15 (IL-15) is highly upregulated in the epithelium and the lamina propria of CeD patients [99]. It can abrogate tolerance to dietary antigens because effector T cells become resistant to inhibition by regulatory T cells [100]. And besides, IL-15 triggers an anti-apoptotic pathway in human intraepithelial lymphocytes [101] (Figure 1, point 7).
AMG714 is the first investigated anti-IL-15 monoclonal antibody. In the first phase 2a clinical trial in CeD patients on a GFD. Treatments were administered by two subcutaneous injections every 2 weeks for 10 weeks (total six doses) and patients without severe villous atrophy at baseline received a gluten challenge (2-4 g daily) during weeks 2-12. It was shown that AMG714 did not prevent mucosal injury due to gluten challenge in comparison to the placebo group, at either 150 and 300 mg, however a smaller increase of IEL was observed at 300 mg and less symptoms in the treatment group (NCT02637141) [102]. Furthermore, in patients with RCD type 2, a phase 2 clinical trial found no difference in the AMG714 group in terms of reduction of aberrant intraepithelial lymphocytes from baseline (NCT02633020) [103].
A potential immunomodulatory is Rituximab, the anti-CD20 antibody. CD20 is a B cell marker and B cells are involved in the pathogenesis of CeD due to the production of various antibodies (Figure 1, point 8). Two case reports have shown a clinical and biological improvement of CeD in patients treated with Rituximab but clinical trials are missing [104,105].

5.2.2. Promote immuno tolerance

A T cell-driven adaptive immune response is directed against deamidated gluten peptides. One of the goals of the novel therapeutic development in CeD is to suppress this response (Figure 1, point 6).
The possibility of restoring immune tolerance to gluten in CeD patients has been recently considered. Nexvax2 is the first peptide-based immunotherapy that aims to suppress or delete disease-causing antigen-specific CD4+ T cells.
In two phase 1 trials, Nexvax2 was administered intradermal, and it has been reported that this drug at doses of 60 µg or higher caused an acute first-dose gastrointestinal reaction (i.e. diarrhoea or nausea) and transiently elevated blood concentrations of IL-2, IL-10. However, with stepwise dose escalation, there were no differences in symptoms between the Nexvax2 group and placebo [106]. In phase 2, a randomized, double-blind, placebo-controlled clinical study, Nexvax2 was stopped after an interim analysis showed that Nexvax2 did not provide statistically significant protection from gluten-induced symptoms (NCT03644069) [107].
TIMP-GLIA (or TAK-101) is a native gliadin encapsulated in negatively charged poly (dl-lactide-co-glycolic acid) nanoparticles. The induction of sustained unresponsiveness to gluten was observed in mouse models with gliadin sensitivity after TIMP-GLIA injection. It was reported inhibition of the proliferation of cytokine IL2, IFNγ, and IL17 secretion of gliadin-stimulated T cells [108]. In the phase 1 study, the intravenous administration of TAK-101 was well tolerated with no profound adverse effect (NCT03486990). A change from baseline in circulating gliadin-specific interferon-γ-producing cells at day 6 of gluten challenge, in patients with CeD, was instead analysed in a phase 2 study. It included 33 patients who completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo. As secondary endpoint, Vh:Cd deteriorated in the placebo group (-0.63, P = .002), but not in the TAK-101 group (-0.18, P = .110) (NCT03738475) [109].

6. Conclusions

In the last 20 years commercial drug development for CeD has accelerated and included investigational products repurposed from other diseases as well as novel antigen-specific immunotherapies applicable only to CeD but instructive for other diseases driven by antigen-specific CD4+ T cells. A wide range of drug candidates have been evaluated in preclinical studies and small phase 1/2a primarily intended to assess safety, but very few have attracted the substantial investment needed for large phase 2 and phase 3 efficacy studies. The recent FDA statement focuses attention on the unmet needs of adult CeD patients with persistent mucosal injury and symptoms attributed to gluten ingestion. Patient selection and efficacy of pharmaceutical adjuvants to GFD would therefore be expected to require gastroenterologists to confirm CeD diagnosis in patients on GFD and also provide objective evidence of mucosal injury despite adherence to GFD.
Advent of rigorous double-blind randomised controlled trials has been transformative for clinical CeD researchers and patients. Efficacy of GFD has come under greater scrutiny challenging the long-held view that strict GFD alone is adequate treatment for almost all CeD patients. Many clinical trials sites and patients especially those in the United States and Oceania previously unable to engage in CeD research have had the opportunity to reshape clinical care of CeD. Commercial drug developers responding to the standards demanded by regulatory authorities have driven re-evaluation of traditional assessments of histology and stimulated discovery of new biomarkers linked to gluten exposure such as IL-2 overlooked in earlier academic studies.
Drug approvals for CeD may be within five years and are likely to be in the United States before other regions because of the leading role of the FDA and payers willing to meet the cost of pharmaceuticals. Establishing adequate clinical resources to appropriately prescribe new therapies for CeD presents a major challenge. Many individuals in the community affected by CeD remain undiagnosed, few gastroenterologists have deep understanding of CeD, the quality of histology necessary to assess duodenal mucosal injury in patients on GFD is questionable in many centres, and high quality economic data to support applications for funding of CeD drugs is often lacking. Only recently has attention shifted to consider resourcing CeD care necessary for the pharmaceutical era [110].
Novel drugs present the potential for non-dietary therapy for CeD that could improve on the efficacy of GFD in those cases where it is not possible to resolve symptoms and gluten damage. In the future, pharmaceutical could eventually substitute or lessen the rigorous adherence to GFD now necessary for mucosal recovery.

Author Contributions

Zingone F and Anderson R designed the manuscript. Crepaldi M collected data. Crepaldi M, Zingone F and wrote the manuscript. Palo M, Maniero D, Bertin L and Savarino EV revised and approved the final version.

Data Availability Statement

no new data were created for this review.

Acknowledgments

none.

Conflicts of Interest

FZ: has served as speaker for Werfen, EG Stada Group, Fresenius Kabi, Kedrion, Janssen, Pfizer, Takeda, Unifarco, Malesci, Galapagos; has served as consultant for Galapagos and Takeda. RA: has served as consultant for Takeda Pharmaceutical Company Ltd /Millennium Pharmaceuticals, Kanyos Bio Inc, GSK, Allero Therapeutics BV, TregTherapeutics, Inc, Bioniz Therapeutics, Inc, Bristol- Myers Squibb Australia Pty Ltd, Immunic AG, DBV, Pecigen ActoBio, Vaccitech, Amyra and EVOQ Therapeutics. RPA is founder and shareholder oNovoviah Pharmaceuticals, and is the inventor of Patents relating to the diagnosis and treatment of coeliac disease. EVS: has served as speaker for Abbvie, AGPharma, Alfasigma, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Unifarco; has served as consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Falk, Fresenius Kabi, Janssen, Merck & Co, Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; hes received research support from Reckitt Benckiser, SILA, Sofar, Unifarco. MC, MP, DM, LB declare no conflict of interest.

References

  1. Singh, P.; Arora, A.; Strand, T.A.; Leffler, D.A.; Catassi, C.; Green, P.H.; Kelly, C.P.; Ahuja, V.; Makharia, G.K. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2018, 16, 823–836.e2. [Google Scholar] [CrossRef] [PubMed]
  2. Fasano, A.; Catassi, C. Clinical practice. Celiac disease. New Engl. J. Med. 2012, 367, 2419–2426. [Google Scholar] [CrossRef] [PubMed]
  3. Lo, W.; Sano, K.; Lebwohl, B.; Diamond, B.; Green, P.H. Changing Presentation of Adult Celiac Disease. Dig. Dis. Sci. 2003, 48, 395–398. [Google Scholar] [CrossRef] [PubMed]
  4. Megiorni, F.; Pizzuti, A. HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. J. Biomed. Sci. 2012, 19, 88–88. [Google Scholar] [CrossRef] [PubMed]
  5. Sollid, L.M.; Lie, B.A. Celiac Disease Genetics: Current Concepts and Practical Applications. Clin. Gastroenterol. Hepatol. 2005, 3, 843–851. [Google Scholar] [CrossRef] [PubMed]
  6. Romanos, J.; van Diemen, C.C.; Nolte, I.M.; Trynka, G.; Zhernakova, A.; Fu, J.; Bardella, M.T.; Barisani, D.; McManus, R.; van Heel, D.A.; et al. Analysis of HLA and Non-HLA Alleles Can Identify Individuals at High Risk for Celiac Disease. Gastroenterology 2009, 137, 834–840. [Google Scholar] [CrossRef]
  7. Kaukinen, K.; Partanen, J.; Mäki, M.; Collin, P. Hla-Dq Typing in The Diagnosis of Celiac Disease. Am. J. Gastroenterol. 2002, 97, 695–699. [Google Scholar] [CrossRef] [PubMed]
  8. Tye-Din, J.A.; Stewart, J.A.; Dromey, J.A.; Beissbarth, T.; van Heel, D.A.; Tatham, A.; Henderson, K.; Mannering, S.I.; Gianfrani, C.; Jewell, D.P.; et al. Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease. Sci. Transl. Med. 2010, 2, 41ra51. [Google Scholar] [CrossRef] [PubMed]
  9. Voisine, J.; Abadie, V. Interplay Between Gluten, HLA, Innate and Adaptive Immunity Orchestrates the Development of Coeliac Disease. Front. Immunol. 2021, 12, 674313. [Google Scholar] [CrossRef]
  10. Schuppan, D.; Junker, Y.; Barisani, D. Celiac Disease: From Pathogenesis to Novel Therapies. Gastroenterology 2009, 137, 1912–1933. [Google Scholar] [CrossRef]
  11. Green, P.H.; Cellier, C. Celiac Disease. New Engl. J. Med. 2007, 357, 1731–1743. [Google Scholar] [CrossRef] [PubMed]
  12. Hisamatsu, T.; Erben, U.; Kühl, A.A. The Role of T-Cell Subsets in Chronic Inflammation in Celiac Disease and Inflammatory Bowel Disease Patients: More Common Mechanisms or More Differences? Inflamm. Intest. Dis. 2016, 1, 52–62. [Google Scholar] [CrossRef] [PubMed]
  13. Goel, G.; Tye-Din, J.A.; Qiao, S.-W.; Russell, A.K.; Mayassi, T.; Ciszewski, C.; Sarna, V.K.; Wang, S.; Goldstein, K.E.; Dzuris, J.L.; et al. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci. Adv. 2019, 5, eaaw7756. [Google Scholar] [CrossRef] [PubMed]
  14. Goel, G.; Daveson, A.J.M.; E Hooi, C.; A Tye-Din, J.; Wang, S.; Szymczak, E.; Williams, L.J.; Dzuris, J.L.; Neff, K.M.; E Truitt, K.; et al. Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clin. Exp. Immunol. 2020, 199, 68–78. [Google Scholar] [CrossRef] [PubMed]
  15. Tye-Din, J.A.; Daveson, A.J.M.; Ee, H.C.; Goel, G.; MacDougall, J.; Acaster, S.; Goldstein, K.E.; Dzuris, J.L.; Neff, K.M.; Truitt, K.E.; et al. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Aliment. Pharmacol. Ther. 2019, 50, 901–910. [Google Scholar] [CrossRef] [PubMed]
  16. Tye-Din, J.A.; Daveson, A.J.M.; Goldstein, K.E.; Hand, H.L.; Neff, K.M.; Goel, G.; Williams, L.J.; Truitt, K.E.; Anderson, R.P. Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Med. 2020, 18, 362. [Google Scholar] [CrossRef] [PubMed]
  17. Leonard, M.M.; Silvester, J.A.; Leffler, D.; Fasano, A.; Kelly, C.P.; Lewis, S.K.; Goldsmith, J.D.; Greenblatt, E.; Kwok, W.W.; McAuliffe, W.J.; et al. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology 2020, 160, 720–733. [Google Scholar] [CrossRef] [PubMed]
  18. Zingone, F.; Maimaris, S.; Auricchio, R.; Caio, G.P.I.; Carroccio, A.; Elli, L.; Galliani, E.; Montagnani, M.; Valiante, F.; Biagi, F. Guidelines of the Italian societies of gastroenterology on the diagnosis and management of coeliac disease and dermatitis herpetiformis. Dig. Liver Dis. 2022, 54, 1304–1319. [Google Scholar] [CrossRef] [PubMed]
  19. Christophersen, A.; Zühlke, S.; Lund, E.G.; Snir, O.; Dahal-Koirala, S.; Risnes, L.F.; Jahnsen, J.; Lundin, K.E.A.; Sollid, L.M. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. Adv. Sci. 2021, 8, 2102778. [Google Scholar] [CrossRef]
  20. Daveson, A.J.M.; Popp, A.; Taavela, J.; Goldstein, K.E.; Isola, J.; Truitt, K.E.; Mäki, M.; Anderson, R.P.; Adams, A.; Andrews, J.; et al. Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet. GastroHep 2020, 2, 22–30. [Google Scholar] [CrossRef]
  21. Aziz, I.; E Evans, K.; Papageorgiou, V.; Sanders, D.S. PTH-097 Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? Gut 2011, 59, A163–1. [Google Scholar] [CrossRef]
  22. Tennyson, C.A.; Simpson, S.; Lebwohl, B.; Lewis, S.; Green, P.H.R. Interest in medical therapy for celiac disease. Ther. Adv. Gastroenterol. 2013, 6, 358–364. [Google Scholar] [CrossRef] [PubMed]
  23. Leffler, D.; Kupfer, S.S.; Lebwohl, B.; Bugin, K.; Griebel, D.; Lathrop, J.T.; Lee, J.J.; Mulberg, A.E.; Papadopoulos, E.; Tomaino, J.; et al. Development of Celiac Disease Therapeutics: Report of the Third Gastroenterology Regulatory Endpoints and Advancement of Therapeutics Workshop. Gastroenterology 2016, 151, 407–411. [Google Scholar] [CrossRef]
  24. https://www.fda.gov/. Available online: https://www.fda.gov/regulatory-information/search-fdaguidance-documents/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet (accessed on 1 August 2023).
  25. Catassi, C.; Rossini, M.; Ratsch, I.M.; Bearzi, I.; Santinelli, A.; Castagnani, R.; Pisani, E.; Coppa, G.V.; Giorgi, P.L. Dose dependent effects of protracted ingestion of small amounts of gliadin in coeliac disease children: a clinical and jejunal morphometric study. Gut 1993, 34, 1515–1519. [Google Scholar] [CrossRef] [PubMed]
  26. Catassi, C.; Fabiani, E.; Iacono, G.; D'Agate, C.; Francavilla, R.; Biagi, F.; Volta, U.; Accomando, S.; Picarelli, A.; De Vitis, I.; et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am. J. Clin. Nutr. 2007, 85, 160–166. [Google Scholar] [CrossRef] [PubMed]
  27. Akobeng, A.K.; Thomas, A.G. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment. Pharmacol. Ther. 2008, 27, 1044–1052. [Google Scholar] [CrossRef] [PubMed]
  28. Silvester, J.A.; Comino, I.; Kelly, C.P.; Sousa, C.; Duerksen, D.R. Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten. Gastroenterology 2020, 158, 1497. [Google Scholar] [CrossRef] [PubMed]
  29. Fernández-Bañares, F.; Beltrán, B.; Salas, A.; Comino, I.; Ballester-Clau, R.; Ferrer, C.; Molina-Infante, J.; Rosinach, M.; Modolell, I.; Rodríguez-Moranta, F.; et al. Persistent Villous Atrophy in De Novo Adult Patients With Celiac Disease and Strict Control of Gluten-Free Diet Adherence: A Multicenter Prospective Study (CADER Study). Am. J. Gastroenterol. 2021, 116, 1036–1043. [Google Scholar] [CrossRef] [PubMed]
  30. Syage, J.A.; Kelly, C.P.; Dickason, M.A.; Ramirez, A.C.; Leon, F.; Dominguez, R.; Sealey-Voyksner, J.A. Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am. J. Clin. Nutr. 2018, 107, 201–207. [Google Scholar] [CrossRef]
  31. Taavela, J.; Koskinen, O.; Huhtala, H.; Lähdeaho, M.-L.; Popp, A.; Laurila, K.; Collin, P.; Kaukinen, K.; Kurppa, K.; Mäki, M. Validation of Morphometric Analyses of Small-Intestinal Biopsy Readouts in Celiac Disease. PLOS ONE 2013, 8, e76163. [Google Scholar] [CrossRef]
  32. Leonard, M.M.; Silvester, J.A.; Leffler, D.; Fasano, A.; Kelly, C.P.; Lewis, S.K.; Goldsmith, J.D.; Greenblatt, E.; Kwok, W.W.; McAuliffe, W.J.; et al. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology 2021, 160, 720–733.e8. [Google Scholar] [CrossRef] [PubMed]
  33. Zingone, F.; Swift, G.L.; Card, T.R.; Sanders, D.S.; Ludvigsson, J.F.; Bai, J.C. Psychological morbidity of celiac disease: A review of the literature. United Eur. Gastroenterol. J. 2015, 3, 136–145. [Google Scholar] [CrossRef] [PubMed]
  34. Nachman, F.; del Campo, M.P.; González, A.; Corzo, L.; Vázquez, H.; Sfoggia, C.; Smecuol, E.; Sánchez, M.I.P.; Niveloni, S.; Sugai, E.; et al. Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. Dig. Liver Dis. 2010, 42, 685–691. [Google Scholar] [CrossRef] [PubMed]
  35. Barratt, S.M.; Leeds, J.S.; Sanders, D.S. Quality of life in Coeliac Disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved. J. Gastrointestin Liver Dis. 2011, 20, 241–245. [Google Scholar] [PubMed]
  36. Burger, J.P.; de Brouwer, B.; IntHout, J.; Wahab, P.J.; Tummers, M.; Drenth, J.P. Systematic review with meta-analysis: Dietary adherence influences normalization of health-related quality of life in coeliac disease. Clin. Nutr. 2017, 36, 399–406. [Google Scholar] [CrossRef] [PubMed]
  37. Marsilio, I.; Canova, C.; D’odorico, A.; Ghisa, M.; Zingone, L.; Lorenzon, G.; Savarino, E.V.; Zingone, F. Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet. Nutrients 2020, 12, 2981. [Google Scholar] [CrossRef]
  38. Canova, C.; Rosato, I.; Marsilio, I.; Valiante, F.; Zorzetto, V.; Cataudella, G.; D’odorico, A.; Zingone, F. Quality of Life and Psychological Disorders in Coeliac Disease: A Prospective Multicentre Study. Nutrients 2021, 13, 3233. [Google Scholar] [CrossRef]
  39. Zingone, F.; Secchettin, E.; Marsilio, I.; Valiante, F.; Zorzetto, V.; Cataudella, G.; D'Odorico, A.; Canova, C. Clinical features and psychological impact of celiac disease at diagnosis. Dig. Liver Dis. 2021, 53, 1565–1570. [Google Scholar] [CrossRef]
  40. Ciccone, A.; Gabrieli, D.; Cardinale, R.; Di Ruscio, M.; Vernia, F.; Stefanelli, G.; Necozione, S.; Melideo, D.; Viscido, A.; Frieri, G.; et al. Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet. Digestion 2019, 100, 262–268. [Google Scholar] [CrossRef]
  41. Tortora, R.; Capone, P.; De Stefano, G.; Imperatore, N.; Gerbino, N.; Donetto, S.; Monaco, V.; Caporaso, N.; Rispo, A. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment. Pharmacol. Ther. 2015, 41, 352–359. [Google Scholar] [CrossRef]
  42. Rispo, A.; Imperatore, N.; Guarino, M.; Tortora, R.; Alisi, A.; Cossiga, V.; Testa, A.; Ricciolino, S.; Fiorentino, A.; Morisco, F. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. Liver Int. 2020, 41, 788–798. [Google Scholar] [CrossRef] [PubMed]
  43. Ehteshami M, Shakerhosseini R, Sedaghat F, Hedayati M, Eini-Zinab H, Hekmatdoost A. The Effect of Gluten Free Diet on Components of Metabolic Syndrome: A Randomized Clinical Trial. Asian Pac J Cancer Prev. 2018, 19, 2979–2984. [CrossRef] [PubMed]
  44. García-Manzanares A, Lucendo AJ. Nutritional and dietary aspects of celiac disease. Nutr. Clin. Pract. 2011, 26, 163–173. [CrossRef] [PubMed]
  45. Ukkola A, Mäki M, Kurppa K, Collin P, Huhtala H, Kekkonen L, Kaukinen K Patients’ experiences and perceptions of living with coeliac disease - implications for optimizing care. J Gastrointestin Liver Dis. march 2012, 21, 17–22.
  46. Al-Toma, A.; Volta, U.; Auricchio, R.; Castillejo, G.; Sanders, D.S.; Cellier, C.; Mulder, C.J.; Lundin, K.E.A. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur. Gastroenterol. J. 2019, 7, 583–613. [Google Scholar] [CrossRef] [PubMed]
  47. de Lourdes Moreno, M.; Cebolla, Á.; Muñoz-Suano, A.; Carrillo-Carrion, C.; Comino, I.; Pizarro, Á.; León, F.; Rodríguez-Herrera, A.; Sousa, C. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut 2017, 66, 250–257. [Google Scholar] [CrossRef] [PubMed]
  48. Tye-Din, J.A. Review article: Follow-up of coeliac disease. Aliment. Pharmacol. Ther. 2022, 56, S49–S63. [Google Scholar] [CrossRef] [PubMed]
  49. Kurien G, Jamil RT, Preuss CV. Dapsone. StatPearls Publishing. Treasure Island (FL), USA, 2023.
  50. Daveson, A.J.M.; Popp, A.; Taavela, J.; Goldstein, K.E.; Isola, J.; Truitt, K.E.; Mäki, M.; Anderson, R.P.; Adams, A.; Andrews, J.; et al. Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet. GastroHep 2020, 2, 22–30. [Google Scholar] [CrossRef]
  51. Adelman, D.C.; Murray, J.; Wu, T.-T.; Mäki, M.; Green, P.H.; Kelly, C.P. Measuring Change In Small Intestinal Histology In Patients With Celiac Disease. Am. J. Gastroenterol. 2018, 113, 339–347. [Google Scholar] [CrossRef]
  52. Anderson, R.P.; Goel, G.; Hardy, M.Y.; Russell, A.K.; Wang, S.; Szymczak, E.; Zhang, R.; E Goldstein, K.; Neff, K.M.; E Truitt, K.; et al. Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. Clin. Exp. Immunol. 2021, 204, 321–334. [Google Scholar] [CrossRef]
  53. Zühlke, S.; Risnes, L.F.; Dahal-Koirala, S.; Christophersen, A.; Sollid, L.M.; Lundin, K.E. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. United Eur. Gastroenterol. J. 2019, 7, 1337–1344. [Google Scholar] [CrossRef] [PubMed]
  54. A Tye-Din, J.; I Skodje, G.; Sarna, V.K.; Dzuris, J.L.; Russell, A.K.; Goel, G.; Wang, S.; E Goldstein, K.; Williams, L.J.; Sollid, L.M.; et al. Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. United Eur. Gastroenterol. J. 2020, 8, 108–118. [Google Scholar] [CrossRef]
  55. Strehl, C.; Ehlers, L.; Gaber, T.; Buttgereit, F. Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System. Front. Immunol. 2019, 10, 1744. [Google Scholar] [CrossRef] [PubMed]
  56. Green, P.H.; Paski, S.; Ko, C.W.; Rubio-Tapia, A. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. Gastroenterology 2022, 163, 1461–1469. [Google Scholar] [CrossRef] [PubMed]
  57. Abbas, A.; Shahab, T.; Sherwani, R.K.; Alam, S. Addition of a Short Course of Prednisolone to a Gluten-Free Diet vs. Gluten-Free Diet Alone in Recovery of Celiac Disease: A Pilot Randomized Controlled Trial. Cureus 2018, 10, e2118. [Google Scholar] [CrossRef]
  58. Ibrahim, A.A.; Kenyon, V.B.; Fasano, A.; Leonard, M.M. Budesonide and the Gluten Containing Elimination Diet as Treatments for Non-responsive Celiac Disease in Children. J. Pediatr. Gastroenterol. Nutr. 2022, 75, 616–622. [Google Scholar] [CrossRef]
  59. Therrien, A.; Silvester, J.A.; Leonard, M.M.; Leffler, D.A.; Fasano, A.; Kelly, C.P. Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease. Dig. Dis. Sci. 2021, 66, 1989–1997. [Google Scholar] [CrossRef]
  60. Mukewar, S.S.; Sharma, A.; Rubio-Tapia, A.; Wu, T.-T.; Jabri, B.; A Murray, J. Open-Capsule Budesonide for Refractory Celiac Disease. Am. J. Gastroenterol. 2017, 112, 959–967. [Google Scholar] [CrossRef]
  61. Malamut, G.; Afchain, P.; Verkarre, V.; Lecomte, T.; Amiot, A.; Damotte, D.; Bouhnik, Y.; Colombel, J.F.; Delchier, J.C.; Allez, M.; et al. Presentation and Long-Term Follow-up of Refractory Celiac Disease: Comparison of Type I With Type II. Gastroenterology 2009, 136, 81–90. [Google Scholar] [CrossRef]
  62. Jamma, S.; Rubio–Tapia, A.; Kelly, C.P.; Murray, J.; Najarian, R.; Sheth, S.; Schuppan, D.; Dennis, M.; Leffler, D.A. Celiac Crisis Is a Rare but Serious Complication of Celiac Disease in Adults. Clin. Gastroenterol. Hepatol. 2010, 8, 587–590. [Google Scholar] [CrossRef]
  63. Antiga, E.; Caproni, M. The diagnosis and treatment of dermatitis herpetiformis. Clin. Cosmet. Investig. Dermatol. 2015, ume 8, 257–265. [Google Scholar] [CrossRef]
  64. Görög, A.; Antiga, E.; Caproni, M.; Cianchini, G.; De, D.; Dmochowski, M.; Dolinsek, J.; Drenovska, K.; Feliciani, C.; Hervonen, K.; et al. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad. Dermatol. Venereol. 2021, 35, 1251–1277. [Google Scholar] [CrossRef] [PubMed]
  65. Levescot, A.; Malamut, G.; Cerf-Bensussan, N. Immunopathogenesis and environmental triggers in coeliac disease. Gut 2022, 71, 2337–2349. [Google Scholar] [CrossRef] [PubMed]
  66. Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø et al. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New Engl. J. Med. 2021, 385, 35–45. [CrossRef] [PubMed]
  67. Siegel, M.; Garber, M.E.; Spencer, A.G.; Botwick, W.; Kumar, P.; Williams, R.N.; Kozuka, K.; Shreeniwas, R.; Pratha, V.; Adelman, D.C. Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials. Dig. Dis. Sci. 2011, 57, 440–450. [Google Scholar] [CrossRef] [PubMed]
  68. Lähdeaho, M.-L.; Kaukinen, K.; Laurila, K.; Vuotikka, P.; Koivurova, O.-P.; Kärjä-Lahdensuu, T.; Marcantonio, A.; Adelman, D.C.; Mäki, M. Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease. Gastroenterology 2014, 146, 1649–1658. [Google Scholar] [CrossRef] [PubMed]
  69. Murray, J.A.; Kelly, C.P.; Green, P.H.; Marcantonio, A.; Wu, T.-T.; Mäki, M.; Adelman, D.C.; Ansari, S.; Ayub, K.; Basile, A.; et al. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease. Gastroenterology 2017, 152, 787–798. [Google Scholar] [CrossRef]
  70. Syage, J.A.; Murray, J.A.; Green, P.H.R.; Khosla, C. Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet. Dig. Dis. Sci. 2017, 62, 2428–2432. [Google Scholar] [CrossRef] [PubMed]
  71. Murray, J.A.; Syage, J.A.; Wu, T.-T.; Dickason, M.A.; Ramos, A.G.; Van Dyke, C.; Horwath, I.; Lavin, P.T.; Mäki, M.; Hujoel, I.; et al. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology 2022, 163, 1510–1521.e6. [Google Scholar] [CrossRef]
  72. Pultz, I.S.; Hill, M.; Vitanza, J.M.; Wolf, C.; Saaby, L.; Liu, T.; Winkle, P.; Leffler, D.A. Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease. Gastroenterology 2021, 161, 81–93.e3. [Google Scholar] [CrossRef]
  73. Salden, B.N.; Monserrat, V.; Troost, F.J.; Bruins, M.J.; Edens, L.; Bartholomé, R.; Haenen, G.R.; Winkens, B.; Koning, F.; Masclee, A.A. Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Aliment. Pharmacol. Ther. 2015, 42, 273–285. [Google Scholar] [CrossRef] [PubMed]
  74. König, J.; Holster, S.; Bruins, M.J.; Brummer, R.J. Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. Sci. Rep. 2017, 7, 1–7. [Google Scholar] [CrossRef] [PubMed]
  75. Tack GJ, van de Water JMW, Bruins MJ, Kooy-Winkelaar EMC, van Bergen J, Bonnet P, Vreugdenhil AC, Korponay-Szabo I, Edens L, von Blomberg BM et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World J. Gastroenterol. 2013, 19, 5837–5847. [CrossRef] [PubMed]
  76. https://imux.com/. Available online: https://imux.com/immunic-presents-clinical-and-preclinical-data-for-imu-856-at-digestive-disease-week-2023-including-its-molecular-mode-of-action/ (accessed on 18 July 2023).
  77. https://www.anzctr.org.au/. Available online: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380021&isReview=true (accessed on 11 October 2023).
  78. https://ir.imux.com/. Available online: https://ir.imux.com/2023-05-04-Immunic-Reports-Positive-Results-From-Phase-1b-Clinical-Trial-of-IMU-856-in-Celiac-Disease,-Providing-Clinical-Proof-of-Concept-for-New-Therapeutic-Approach-to-Gastrointestinal-Disorders (accessed on 18 July 2023).
  79. https://imux.com/. Available online: https://imux.com/immunic-reports-positive-results-from-phase-1b-clinical-trial-of-imu-856-in-celiac-disease-providing-clinical-proof-of-concept-for-new-therapeutic-approach-to-gastrointestinal-disorders/ (accessed on 18 July 2023).
  80. Hoilat, G.J.; Altowairqi, A.K.; Ayas, M.F.; Alhaddab, N.T.; Alnujaidi, R.A.; Alharbi, H.A.; Alyahyawi, N.; Kamal, A.; Alhabeeb, H.; Albazee, E.; et al. Larazotide acetate for treatment of celiac disease: A systematic review and meta- analysis of randomized controlled trials. Clin. Res. Hepatol. Gastroenterol. 2021, 46, 101782. [Google Scholar] [CrossRef] [PubMed]
  81. https://www.biospace.com/. Available online: https://www.biospace.com/article/poor-results-end-9-meters-phase-iii-trial-for-larazotide/ (accessed on 10 October 2023).
  82. Sample, D.A.; Sunwoo, H.H.; Huynh, H.Q.; Rylance, H.L.; Robert, C.L.; Xu, B.-W.; Kang, S.H.; Gujral, N.; Dieleman, L.A. AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease. Dig. Dis. Sci. 2017, 62, 1277–1285. [Google Scholar] [CrossRef] [PubMed]
  83. McCarville, J.L.; Nisemblat, Y.; Galipeau, H.J.; Jury, J.; Tabakman, R.; Cohen, A.; Naftali, E.; Neiman, B.; Halbfinger, E.; Murray, J.A.; et al. BL-7010 Demonstrates Specific Binding to Gliadin and Reduces Gluten-Associated Pathology in a Chronic Mouse Model of Gliadin Sensitivity. PLOS ONE 2014, 9, e109972–e109972. [Google Scholar] [CrossRef] [PubMed]
  84. Pinier, M.; Fuhrmann, G.; Galipeau, H.J.; Rivard, N.; Murray, J.A.; David, C.S.; Drasarova, H.; Tuckova, L.; Leroux, J.; Verdu, E.F. The Copolymer P(HEMA-co-SS) Binds Gluten and Reduces Immune Response in Gluten-Sensitized Mice and Human Tissues. Gastroenterology 2012, 142, 316–325. [Google Scholar] [CrossRef] [PubMed]
  85. Yokoyama, S.; Perera, P.-Y.; Waldmann, T.A.; Hiroi, T.; Perera, L.P. Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease. J. Clin. Immunol. 2013, 33, 586–594. [Google Scholar] [CrossRef] [PubMed]
  86. Grewal, J.K.; Kassardjian, A.; A Weiss, G. Successful novel use of tofacitinib for type II refractory coeliac disease. BMJ Case Rep. 2022, 15, e244692. [Google Scholar] [CrossRef]
  87. Verdu, E.F.; Schuppan, D. Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment. Gastroenterology 2021, 161, 1395–1411. [Google Scholar] [CrossRef]
  88. Caminero, A.; Galipeau, H.J.; McCarville, J.L.; Johnston, C.W.; Bernier, S.P.; Russell, A.K.; Jury, J.; Herran, A.R.; Casqueiro, J.; Tye-Din, J.A.; et al. Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity. Gastroenterology 2016, 151, 670–683. [Google Scholar] [CrossRef] [PubMed]
  89. Caminero, A.; Meisel, M.; Jabri, B.; Verdu, E.F. Mechanisms by which gut microorganisms influence food sensitivities. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 7–18. [Google Scholar] [CrossRef] [PubMed]
  90. Hiippala, K.; Jouhten, H.; Ronkainen, A.; Hartikainen, A.; Kainulainen, V.; Jalanka, J.; Satokari, R. The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation. Nutrients 2018, 10, 988. [Google Scholar] [CrossRef] [PubMed]
  91. Francavilla, R.; De Angelis, M.; Rizzello, C.G.; Cavallo, N.; Bello, F.D.; Gobbetti, M. Selected Probiotic Lactobacilli Have the Capacity To Hydrolyze Gluten Peptides during Simulated Gastrointestinal Digestion. Appl. Environ. Microbiol. 2017, 83, e00376-17. [Google Scholar] [CrossRef] [PubMed]
  92. McCarville, J.L.; Dong, J.; Caminero, A.; Bermudez-Brito, M.; Jury, J.; Murray, J.A.; Duboux, S.; Steinmann, M.; Delley, M.; Tangyu, M.; et al. A Commensal Bifidobacterium longum Strain Prevents Gluten-Related Immunopathology in Mice through Expression of a Serine Protease Inhibitor. Appl. Environ. Microbiol. 2017, 83, e01323-17. [Google Scholar] [CrossRef] [PubMed]
  93. Olivares, M.; Castillejo, G.; Varea, V.; Sanz, Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br. J. Nutr. 2014, 112, 30–40. [Google Scholar] [CrossRef] [PubMed]
  94. Quagliariello, A.; Aloisio, I.; Cionci, N.B.; Luiselli, D.; D’auria, G.; Martinez-Priego, L.; Pérez-Villarroya, D.; Langerholc, T.; Primec, M.; Mičetić-Turk, D.; et al. Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study. Nutrients 2016, 8, 660. [Google Scholar] [CrossRef]
  95. Klemenak, M.; Dolinšek, J.; Langerholc, T.; Di Gioia, D.; Mičetić-Turk, D. Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease. Dig. Dis. Sci. 2015, 60, 3386–3392. [Google Scholar] [CrossRef] [PubMed]
  96. Primec, M.; Klemenak, M.; Di Gioia, D.; Aloisio, I.; Cionci, N.B.; Quagliariello, A.; Gorenjak, M.; Mičetić-Turk, D.; Langerholc, T. Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-α and short-chain fatty acids. Clin. Nutr. 2019, 38, 1373–1381. [Google Scholar] [CrossRef]
  97. Smecuol, E.; Hwang, H.J.; Sugai, E.; Corso, L.; Cherñavsky, A.C.; Bellavite, F.P.; González, A.; Vodánovich, F.; Moreno, M.L.; Vázquez, H.; et al. Exploratory, Randomized, Double-blind, Placebo-controlled Study on the Effects of Bifidobacterium infantis Natren Life Start Strain Super Strain in Active Celiac Disease. J. Clin. Gastroenterol. 2013, 47, 139–147. [Google Scholar] [CrossRef]
  98. Seiler, C.L.; Kiflen, M.; Stefanolo, J.P.; Bai, J.C.; Bercik, P.; Kelly, C.P.; Verdu, E.F.; Moayyedi, P.; Pinto-Sanchez, M.I. Probiotics for Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am. J. Gastroenterol. 2020, 115, 1584–1595. [Google Scholar] [CrossRef] [PubMed]
  99. Mention, J.-J.; Ahmed, M.B.; Begue, B.; Barbe, U.; Verkarre, V.; Asnafi, V.; Colombel, J.-F.; Cugnenc, P.-H.; Ruemmele, F.M.; Mcintyre, E.; et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003, 125, 730–745. [Google Scholar] [CrossRef] [PubMed]
  100. DePaolo, R.W.; Abadie, V.; Tang, F.; Fehlnerpeach, H.; Hall, J.A.; Wang, W.; Marietta, E.V.; Kasarda, D.D.; Waldmann, T.A.; A Murray, J.; et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471, 220–224. [Google Scholar] [CrossRef]
  101. Malamut, G.; El Machhour, R.; Montcuquet, N.; Martin-Lannerée, S.; Dusanter-Fourt, I.; Verkarre, V.; Mention, J.-J.; Rahmi, G.; Kiyono, H.; Butz, E.A.; et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis. J. Clin. Investig. 2010, 120, 2131–2143. [Google Scholar] [CrossRef] [PubMed]
  102. Lähdeaho, M.-L.; Scheinin, M.; Vuotikka, P.; Taavela, J.; Popp, A.; Laukkarinen, J.; Koffert, J.; Koivurova, O.-P.; Pesu, M.; Kivelä, L.; et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol. Hepatol. 2019, 4, 948–959. [Google Scholar] [CrossRef] [PubMed]
  103. Cellier, C.; Bouma, G.; van Gils, T.; Khater, S.; Malamut, G.; Crespo, L.; Collin, P.; Green, P.H.R.; E Crowe, S.; Tsuji, W.; et al. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol. Hepatol. 2019, 4, 960–970. [Google Scholar] [CrossRef] [PubMed]
  104. Palazzo, C.; Nicaise-Roland, P.; Palazzo, E. Rituximab: An effective treatment for rheumatologic and digestive symptoms of celiac disease? Jt. Bone Spine 2012, 79, 422–423. [Google Scholar] [CrossRef]
  105. Nikiphorou, E.; Hall, F.C. First report of improvement of coeliac disease in a patient with Sjogren's syndrome treated with rituximab. Rheumatology 2014, 53, 1906–1907. [Google Scholar] [CrossRef]
  106. Goel, G.; King, T.; Daveson, A.J.; Andrews, J.M.; Krishnarajah, J.; Krause, R.; Brown, G.J.E.; Fogel, R.; Barish, C.F.; Epstein, R.; et al. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. Lancet Gastroenterol. Hepatol. 2017, 2, 479–493. [Google Scholar] [CrossRef]
  107. A Tye-Din, J.; Daveson, A.J.M.; Goel, G.; E Goldstein, K.; Hand, H.L.; Neff, K.M.; Popp, A.; Taavela, J.; Maki, M.; Isola, J.; et al. Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. Lancet Gastroenterol. Hepatol. 2023, 8, 446–457. [Google Scholar] [CrossRef]
  108. Freitag, T.L.; Podojil, J.R.; Pearson, R.M.; Fokta, F.J.; Sahl, C.; Messing, M.; Andersson, L.C.; Leskinen, K.; Saavalainen, P.; Hoover, L.I.; et al. Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease. Gastroenterology 2020, 158, 1667–1681. [Google Scholar] [CrossRef] [PubMed]
  109. Kelly, C.P.; Murray, J.A.; Leffler, D.A.; Getts, D.R.; Bledsoe, A.C.; Smithson, G.; First, M.R.; Morris, A.; Boyne, M.; Elhofy, A.; et al. TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology 2021, 161, 66–80.e8. [Google Scholar] [CrossRef] [PubMed]
  110. Pinto-Sanchez, M.I.; Silvester, J.A.; Lebwohl, B.; Leffler, D.A.; Anderson, R.P.; Therrien, A.; Kelly, C.P.; Verdu, E.F. Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 875–884. [Google Scholar] [CrossRef] [PubMed]
Preprints 89690 g001
Figure 1. Potential CeD-specific therapeutic targets and corresponding investigational drugs in celiac disease. 1) Glutenase: Latiglutenase, STAN 1, AN-PEP, TAK -062; 2) Gluten sequestration: AGY, BL-7010; 3) Tight junction modulators: Larazotide; 4) tTG inhibition: ZED 1227; 5) HLA DQ2/DQ8 blocking peptide analogues; 6) Promote immuno tolerance: Nexvax2 and TIMP-GLIA; 7) Cytokine inhibition. Anti IL 15 (AMG714), Tofacitinib, anti CCR9R: CCX282-B; 8) Suppression of B cell and T cells: Rituximab and steroids 9) Intestinal regeneration: IMU 856; 10) Gut microbiome: Bifidobacterium longum, Lactobacillus strains. Figure Made in BioRender.com.
Figure 1. Potential CeD-specific therapeutic targets and corresponding investigational drugs in celiac disease. 1) Glutenase: Latiglutenase, STAN 1, AN-PEP, TAK -062; 2) Gluten sequestration: AGY, BL-7010; 3) Tight junction modulators: Larazotide; 4) tTG inhibition: ZED 1227; 5) HLA DQ2/DQ8 blocking peptide analogues; 6) Promote immuno tolerance: Nexvax2 and TIMP-GLIA; 7) Cytokine inhibition. Anti IL 15 (AMG714), Tofacitinib, anti CCR9R: CCX282-B; 8) Suppression of B cell and T cells: Rituximab and steroids 9) Intestinal regeneration: IMU 856; 10) Gut microbiome: Bifidobacterium longum, Lactobacillus strains. Figure Made in BioRender.com.
Preprints 89690 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated